Prognostic value of preoperative inflammatory markers among different molecular subtypes of lower-grade glioma

J Clin Neurosci. 2022 Feb:96:180-186. doi: 10.1016/j.jocn.2021.10.006. Epub 2021 Nov 18.

Abstract

Background: The inflammatory response is closely related to cancer progression and prognosis. The aim of this study was to determine the prognostic value of preoperative inflammatory markers among different molecular subtypes of lower-grade glioma (LGG).

Methods: We performed a retrospective analysis of 214 patients with LGG from 2001 to 2013, evaluating the effect of the neutrophil/lymphocyte ratio (NLR), lymphocyte/monocyte ratio (LMR), platelet/lymphocyte ratio (PLR) and derived NLR (dNLR) on prognosis among different molecular subtypes. Isocitrate dehydrogenase (IDH) and telomerase reverse transcriptase (TERT) promotor mutations were detected by gene sequencing, and Chromosome arms 1p and 19q (1p/19q) codeletion was estimated via fluorescence in situ hybridization.

Results: Survival analysis showed that a high NLR, low LMR, and high dNLR were associated with poor prognosis, while the PLR had no prognostic significance. The subsequent molecular subtype analysis indicated that a high NLR and dNLR predicted worse survival in the IDH mutation only group, a high NLR and PLR predicted worse survival in the IDH and TERT promoter mutation group, and a high PLR was associated with shorter survival in the triple-positive group. Furthermore, univariate and multivariate Cox regression analysis suggested that the dNLR was an independent prognostic factor for LGG. Finally, the prognostic nomogram was developed by integrating the inflammatory marker dNLR and independent clinical risk factors.

Conclusion: The results of this study indicated that a high dNLR was an independent risk factor for overall survival rates in patients with LGG, which may increase prognostic accuracy and improve patient outcomes.

Keywords: Derived neutrophil/lymphocyte ratio (dNLR); Inflammatory markers; Lower-grade glioma; Molecular subtypes.

MeSH terms

  • Biomarkers, Tumor / genetics
  • Glioma* / diagnosis
  • Glioma* / genetics
  • Glioma* / surgery
  • Humans
  • In Situ Hybridization, Fluorescence
  • Isocitrate Dehydrogenase / genetics
  • Neoplasm Grading
  • Prognosis
  • Promoter Regions, Genetic
  • Retrospective Studies
  • Telomerase / genetics

Substances

  • Biomarkers, Tumor
  • Isocitrate Dehydrogenase
  • TERT protein, human
  • Telomerase